The use of monoclonal antibodies (MAbs) has also shown potential as an effective treatment for some cancers, namely in the suppression of glutamine-dependent growth of colorectal cancer cells (KM4008, KM4012 and KM4018) [166] and ASCT2-expressing gastric cancer (KM8094) [56,167]. The gene discussed is SLC1A5; the disease is colorectal cancer.